[Frontiers in Bioscience 15, 180-194, January 1, 2010]

TGF-beta signaling, tumor microenvironment and tumor progression: the butterfly effect

Amit Joshi1, Deliang Cao2

1Department of Medical Microbiology, Immunology, and Cell Biology, SimmonsCooper Cancer Institute, Southern Illinois University School of Medicine. 913 N. Rutledge Street, Springfield, IL 62702, 2Department of Medical Microbiology, Immunology, and Cell Biology, SimmonsCooper Cancer Institute, Southern Illinois University School of Medicine. 913 N. Rutledge Street, Springfield, IL 62702

TABLE OF CONTENTS

1. ABSTRACT
2. Introduction
3. TGF-β signaling pathway
3.1. TGF-β and its receptors
3.2. GF-β signaling through Smads
3.3. Crosstalk with other signaling pathways
4. TGF-β and tumor progression
4.1. TGF-β as a suppressor of tumorigenesis
4.2. TGF-β as a stimulator of malignant progression
4.3. TGF-β and epithelial-to-mesenchymal transformation
5. TGF-β and tumor microenvironment
5.1. TGF-β and tumor immune responses
5.2. TGF-β and tumor angiogenesis
5.3. TGF-β and tumor microenvironment
6. TGF-β signaling as a therapeutic target for human cancer
7. Conclusion
8. References

1. ABSTRACT

Transforming growth factor-beta (TGF-β) signals through receptor serine/threonine kinases and intracellular Smad effectors, regulating numerous epithelial cell processes. TGF-β plays a crucial role in the cancer initiation and progression through tumor cell autonomous signaling and interactions with tumor microenvironment, but is featured with a butterfly effect upon the stages of tumorigenesis. TGF-β signaling acts as a suppressor of epithelial cell tumorigenesis at early stages, but promotes tumor progression by enhancing migration, invasion, and survival of the tumor cells during the later stages. TGF-β signaling also cross-talks with other cell survival signaling pathways. Tumor microenvironment contains many distinct cell types, which substantially influences the tumor cell growth and survival, and the invasion and metastasis. TGF-β in the microenvironment, produced by cancer and/or stromal cells, is high and negatively correlates with disease progression and patient prognosis. Therefore, TGF-β may affect tumor progression by multiple mechanisms in addition to its direct action on tumor cells, and the diversities of TGF-β signaling in tumors imply a need for caution to TGF-β-targeted strategies of tumor prevention and/or therapeutics.